Global Information
회사소개 | 문의 | 비교리스트

세계의 말기 신장질환 시장(2021-2028년)

Global End Stage Renal Disease Market - 2021-2028

리서치사 DataM Intelligence
발행일 On Demand Report 상품 코드 1035388
페이지 정보 영문 180 Pages
가격
US $ 4,350 ₩ 5,230,000 PDF & Excel (Single User License)
US $ 4,850 ₩ 5,832,000 PDF & Excel (Multiple User License)
US $ 7,850 ₩ 9,439,000 PDF & Excel (Enterprise License)


세계의 말기 신장질환 시장(2021-2028년) Global End Stage Renal Disease Market - 2021-2028
발행일 : On Demand Report 페이지 정보 : 영문 180 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

만성 신부전은 말기 신장질환이라고도 불리고, 시간 경과와 함께 신장 기능이 저하해 유해한 영향을 미치는 경우가 있습니다. 대부분의 신부전 환자는 일주일에 몇 번이나 투석 클리닉에서 혈액을 여과하지만, 이것은 시간이 걸리고 고통을 수반하는 위험한 행위입니다. 시장 기업이 개발한 신장질환용 제품의 기술적 진보가 시장 성장 원동력이 될 것으로 예상됩니다. 한편 혈액 투석 치료에 따른 위험이 시장 성장을 저해할 것으로 예상됩니다.

세계의 말기 신장질환(End Stage Renal Disease) 시장에 대해 조사했으며, 시장 개요와 함께 치료와 진단별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업 개요 등을 제공합니다.

목차

제1장 세계의 말기 신장질환 시장 - 조사 방법과 범위

  • 조사 방법
  • 조사 목적과 조사 범위

제2장 세계의 말기 신장질환 시장 - 시장 정의와 개요

제3장 세계의 말기 신장질환 시장 - 주요 요약

  • 치료와 진단별 시장 내역
  • 최종사용자별 시장 내역
  • 지역별 시장 내역

제4장 세계의 말기 신장질환 시장 - 시장 역학

  • 시장에 영향을 미치는 요인
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
    • 영향 분석

제5장 세계의 말기 신장질환 시장 - 업계 분석

  • Porter's Five Forces 분석
  • 역학 분석
  • 상환 분석
  • 미충족 수요

제6장 세계의 말기 신장질환 시장 - COVID-19 분석

  • 시장에서의 COVID-19 분석
    • COVID-19 이전 시장 시나리오
    • COVID-19 현재 시장 시나리오
    • COVID-19 이후 또는 향후 시나리오
  • COVID-19의 가격 역학
  • 수요와 공급 스펙트럼
  • 팬데믹 동안 시장과 관련된 정부 정책
  • 제조업체의 전략적 이니셔티브
  • 결론

제7장 세계의 말기 신장질환 시장 - 치료와 진단별

  • 서론
    • 시장 규모 분석 및 전년대비 성장 분석(%), 치료와 진단별
    • 시장 매력 지수
  • 치료
    • 신장이식
    • 투석
  • 진단
    • 혈액검사
    • 요검사
    • 영상검사
    • 기타

제8장 세계의 말기 신장질환 시장 - 최종사용자별

  • 서론
    • 시장 규모 분석 및 전년대비 성장 분석(%), 최종사용자별
    • 시장 매력 지수
  • 병원 및 진료소
    • 서론
    • 시장 규모 분석, 백만 달러, 2019-2028년 및 전년대비 성장 분석(%), 2020-2028년
  • 투석 센터
  • 기타

제9장 세계의 말기 신장질환 시장 - 지역별

  • 서론
    • 시장 규모 분석, 백만 달러, 2019-2028년 및 전년대비 성장 분석(%), 2020-2028년, 지역별
    • 시장 매력 지수
  • 북미
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%), 치료와 진단별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 최종사용자별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 국가별
  • 유럽
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%), 치료와 진단별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 최종사용자별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 국가별
  • 남미
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%), 치료와 진단별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 최종사용자별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 국가별
  • 아시아태평양
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%), 치료와 진단별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 최종사용자별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 국가별
  • 중동과 아프리카
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%), 치료와 진단별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 최종사용자별

제10장 세계의 말기 신장질환 시장 - 경쟁 상황

  • 주요 발전과 전략
  • 기업 점유율 분석
  • 제품 벤치마크
  • 주목해야 할 주요 기업 리스트
  • 파괴적 기술을 보유한 기업 리스트
  • 스타트업 기업 리스트

제11장 세계의 말기 신장질환 시장 - 기업 개요

  • NxStage Medical
    • 기업 개요
    • 제품 포트폴리오와 개요
    • 주요 하이라이트
    • 재무 개요
  • B Braun Melsungen AG
  • Baxter International Inc
  • Medtronic PLC
  • Fresenius SE & Co. KGaA
  • Nipro Corporation
  • Asahi Kasei Medical Co.
  • Trivitron Healthcare
  • Guangzhou MeCan Medical Limited
  • JMS North America Corporation

제12장 세계의 말기 신장질환 시장 - DataM

  • 부록
  • 당사에 대해
  • 문의
KSM 21.11.16

Market Overview

End-stage renal diseases are associated with disorders related to the kidney and occur during chronic kidney disease, which adversely affects the functioning of the kidney.

The global end stage renal disease market size was valued US$ YY million in 2020 and is estimated to reach US$ YY million by 2028, growing at a CAGR of YY % during the forecast period (2021-2028).

Market Dynamics

Technological advancement products developed by the market players for renal diseases are expected to drive the market growth.

Chronic kidney failure, also known as end-stage renal disease, causes the kidneys to lose function over time, which can be harmful. Most renal failure patients go to dialysis clinics numerous times a week to have their blood filtered, a time-consuming, painful, and dangerous procedure. KidneyX is a public-private partnership established by the US Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN) to accelerate kidney disease prevention, diagnosis, and treatment innovation. The Kidney Project, led by Shuvo Roy, Ph.D. of UC San Francisco and William Fissell, MD of Vanderbilt University Medical Center (VUMC), successfully implanted the smartphone-sized device for the preclinical evaluation of two essential components parts of its artificial kidney, the hemofilter and the bioreactor. KidneyX's Phase 1 Artificial Kidney Prize was presented to the team, one of six winning teams chosen from a worldwide competition for this advancement.

Moreover, the Kidney Project successfully tested the hemofilter, which removes waste products and toxins from the blood and the bioreactor, which simulates other kidney functions such as blood electrolyte balancing, in independent studies. The artificial kidney developed by The Kidney Project will imitate the exceptional quality of life experienced by kidney transplant recipients-the "gold standard" of kidney disease treatment-and improve on it. Additionally, In March 2021, Baxter International Inc. announced the US Food and Drug Administration (FDA) clearance of its next-generation Artificial Kidney 98 dialysis machine, which is designed to be a portable and easy-to-use system to administer hemodialysis (HD) treatments. Therefore, it indicated that companies are taking initiatives to establish a strong footprint and launch technologically advanced products in the market.

Risks associated with the hemodialysis treatment are expected to hamper the market growth.

Certain risks associated with hemodialysis treatment increase when patients undergo HHD alone since no one is there to assist them in the event of a medical emergency. Patients may lose consciousness or become physically unable to rectify the health emergency if needles come out, blood is lost, or blood pressure is very low during solo HHD. During any health emergency, losing consciousness or becoming otherwise disabled could result in serious damage or death. Moreover, due to the length of treatment duration and the fact that therapy is administered when the patient and care partner are asleep, the dangers associated with hemodialysis treatment increase while doing nocturnal therapy. Blood access disconnects and blood loss during sleep, blood clotting due to decreased blood flow or greater treatment time, and delayed response to alarms while waking from sleep are only a few of the hazards. Therefore, ancillary devices and training are required when performing solo HHD.

COVID-19 Impact Analysis

The COVID-19 outbreak has significantly impacted kidney disease incidence and management, including AKI, ESKD, GN, and kidney transplantation. Initial data from China revealed that patients with COVID-19 had a decreased risk of AKI. However, recent studies from North America show a significantly greater incidence, which is likely owing to the higher frequency of concomitant diseases such as hypertension, diabetes, and CKD. Moreover, those who receive outpatient in-center HD are in close contact with other patients and staff multiple times a week, putting them at even greater risk. Clinical presentation is atypical compared with patients not on dialysis, with patients with ESKD presenting without typical symptoms of cough and fever but fatigue and anorexia. The risk of in-hospital death is significantly higher among patients with ESKD than patients without ESKD, with older age and the need for mechanical ventilation increasing risk. Additionally, the pandemic is interrupting the medical supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Dialysis segment is expected to hold the largest market share in end stage renal disease market.

In 2020, the dialysis segment accounted for the highest market share. Dialysis is more convenient and easier to obtain for ESRD patients, and the procedure is completed at home or in a dialysis center. The high prevalence of diabetics, hypertension, rising kidney failures, lack of kidney donors for transplantation, increased funding for better dialysis products and services globally, growing awareness about various kidney failure diseases, and unhealthy lifestyles are the factors expected to boost the market during the forecast period. For instance, according to the American Urology Care Foundation, one in every three adults in the United States is at risk of renal disease. Kidney illness is called the "silent epidemic" because it typically goes unnoticed until it's too late. Kidney disease is commonly caused by high blood pressure and diabetes. Other risk factors for kidney disease include heart disease, obesity, excessive cholesterol, and a family history of renal disease. Kidney stones are the cause of almost 500,000 emergency room visits each year.

Moreover, March is National Kidney Month, when communities across the country raise awareness about kidney illness, according to the National Institute of Diabetes and Digestive and Kidney Diseases. This year's focus is on taking control of one's health and the various elements that affect renal disease management. These organizations conduct awareness education programs such as kidney smart classes, in which renal care experts teach about the causes of kidney illnesses, lifestyle choices, CKD basics, healthy foods, and nutrition. As a result, demand for dialysis has increased, propelling segment growth over the forecast period.

Geographical Analysis

Asia-Pacific region holds the largest market share in the global end stage renal disease market

In 2020, Asia-Pacific accounted for the highest revenue share. The growth in the aging population, lifestyle stress, a large population base, improving quality of diagnosis, and growing patient affordability, presence of high disposable income and the high acceptance rate of technologically improved products and raising blood pressure and diabetes cases in the region are some of the factors due to which the market is expected to boost in the forecast period. For instance, according to the Asian Diabetics Prevention Initiatives, Asia will account for 60 percent of the world's diabetes population by 2020. A bigger contribution from China and India had 113.9 million and 65.1 million adults with diabetes, respectively. Both China and India may have nearly half a billion diabetic people by 2030.

Moreover, a report released by the Indian Government's national health portal indicates that 2.2 lakh new patients with end-stage renal disease (ESRD) are diagnosed each year, resulting in a demand for 3.4 crore dialysis treatments. In India, there were approximately 4,950 dialysis centers, most of which were in the private sector. As a result, the presence of several dialysis clinics in this region and an increase in the number of patients suffering from chronic renal and kidney illnesses are expected to boost market growth over the forecast period.

Competitive Landscape

Major key players in the end-stage renal disease market are: B Braun Melsungen AG, Baxter International Inc, Medtronic PLC, Fresenius SE & Co. KGaA, Nipro Corporation, Asahi Kasei Medical Co., Trivitron Healthcare, Guangzhou MeCan Medical Limited, JMS North America Corporation and NxStage Medical. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which contribute to the growth of the end-stage renal disease market globally. For instance, In June 2021, Baxter launched the Sharesource Analytics 1.0 Digital Health Module to enhance the clinical management of home dialysis patients.

NxStage Medical, Inc.:

Overview:

NxStage Medical, Inc. is an American company that develops, manufactures, and markets systems to treat chronic kidney disease, acute kidney injury, and hypervolemia. It is a subsidiary of Fresenius Medical Care.

Product Portfolio:

System One: The NxStage System One is the portable hemodialysis system specifically designed for patients in their homes and is small enough to travel and bring their treatment supplies.

Why Purchase the Report?

  • Visualize the composition of the global end stage renal disease market segmentation by treatment & diagnosis, end user and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in global end stage renal disease market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of global end stage renal disease market- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global end stage renal disease market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global End Stage Renal Disease Market - By Treatment & Diagnosis

  • Treatment
  • Kidney Transplantation
  • Dialysis
  • Peritoneal Dialysis
  • Hemodialysis
  • Wearable Artificial Kidney
  • Diagnosis
  • Blood Test
  • Urine Test
  • Imaging Test
  • Others

Global End Stage Renal Disease Market - By End user

  • Hospitals &Clinics
  • Dialysis Centres
  • Others

Global End Stage Renal Disease Market - By Region

  • North America
  • South America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Table of Contents

1. Global End Stage Renal Disease Market - Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global End Stage Renal Disease Market - Market Definition and Overview

3. Global End Stage Renal Disease Market - Executive Summary

  • 3.1. Market Snippet by Treatment & Diagnosis
  • 3.2. Market Snippet by End user
  • 3.3. Market Snippet by Region

4. Global End Stage Renal Disease Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological advancement products developed by the market players for renal diseases are expected to drive the market growth.
      • 4.1.1.2. Increasing prevalence of diabetes and hypertension is expected to drive the market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Risks associated with the hemodialysis treatment are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global End Stage Renal Disease Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology Analysis
  • 5.3. Reimbursement Analysis
  • 5.4. Unmet Needs

6. Global End Stage Renal Disease Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global End Stage Renal Disease Market - By Treatment & Diagnosis

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment & Diagnosis
    • 7.1.2. Market Attractiveness Index, By Treatment & Diagnosis Segment
  • 7.2. Treatment
    • 7.2.1. Kidney Transplantation*
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    • 7.2.2. Dialysis
      • 7.2.2.1. Peritoneal Dialysis
      • 7.2.2.2. Hemodialysis
      • 7.2.2.3. Wearable Artificial Kidney
  • 7.3. Diagnosis
    • 7.3.1. Blood Test
    • 7.3.2. Urine Test
    • 7.3.3. Imaging test
    • 7.3.4. Others

8. Global End Stage Renal Disease Market - By End user

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 8.1.2. Market Attractiveness Index, By End user Segment
  • 8.2. Hospital and Clinics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Dialysis Centres
  • 8.4. Others

9. Global End Stage Renal Disease Market - By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment & Diagnosis
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment & Diagnosis
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment & Diagnosis
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment & Diagnosis
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment & Diagnosis
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

10. Global End Stage Renal Disease Market - Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking
  • 10.4. List of Key Companies to Watch
  • 10.5. List of Company with disruptive technology
  • 10.6. List of Start Up Companies

11. Global End Stage Renal Disease Market- Company Profiles

  • 11.1. NxStage Medical*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. B Braun Melsungen AG
  • 11.3. Baxter International Inc
  • 11.4. Medtronic PLC
  • 11.5. Fresenius SE & Co. KGaA
  • 11.6. Nipro Corporation
  • 11.7. Asahi Kasei Medical Co.
  • 11.8. Trivitron Healthcare
  • 11.9. Guangzhou MeCan Medical Limited
  • 11.10. JMS North America Corporation (LIST NOT EXHAUSTIVE)

12. Global End Stage Renal Disease Market - DataM

  • 12.1. Appendix
  • 12.2. About Us
  • 12.3. Contact Us
Back to Top
전화 문의
F A Q